FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296475494> ?p ?o ?g. }

• W4296475494 abstract "Background and Aims ALXN1840 is an oral, copper (Cu)-binding agent that forms a stable tripartite (tetrathiomolybdate-Cu-albumin) complex. This study investigated the efficacy and safety of ALXN1840 for treating Wilson disease (WD) using a novel plasma biomarker of Cu sequestration. Method Patients with WD aged ≥ 12 years (Leipzig score ≥ 4; model for end-stage liver disease score ≤ 13) were randomized 2:1 to ALXN1840 at a starting dose of 15 mg QD with dose adjustments up to 60 mg QD permitted, or standard of care (SoC; penicillamine, trientine and/or zinc) for 48 weeks (W). Prior SoC for > 28 days and 0 – 28 days determined enrolment to Cohorts 1 and 2, respectively. Primary endpoint: mean daily area under the effect-time curve of directly measured non-ceruloplasmin-bound Cu 0 – 48W (dNCC AUEC0–48W). Secondary endpoints: 0 – 48W change in neurological Unified WD rating scale (UWDRS) Part II and III scores, and Clinical Global Impression – Improvement (CGI-I) scores. A pre-specified hierarchical statistical testing method was used to control multiplicity across primary and key secondary endpoints. Adverse events (AEs) were summarized. Results 214 patients enrolled; all had preserved liver function and 79% had neurological symptoms. 207 were treated, 137 with ALXN1840 and 70 with SoC; mean age was 34.3 and 32.1 years, and 59.9% and 52.9% were male, respectively. Mean daily dNCC AUEC0–48W (μmol/L) was 3.2 times greater with ALXN1840 than with SoC overall (least-squares mean [LSM] difference, 2.18 [standard error (SE), 0.244], p < 0.0001), and 2.5 times greater with ALXN1840 for Cohort 1, despite a mean prior SoC duration of > 12 years ([figure 1][1]). UWDRS scores reduced modestly from 0 to 48W (mean [95% confidence interval] change in Part III score for symptomatic patients: ALXN1840, –2.91 [–4.74, –1.09]; SoC, –1.17 [–3.20, 0.86]). No significant between-group differences occurred by 48W. Transformed CGI-I scores improved with ALXN1840 vs SoC at 48W; LSM difference, –0.3 [SE, 0.15], p = 0.0316; outside the multiplicity testing sequence). For 0 – 48W, 100.1 (ALXN1840) and 86.5 (SoC) patients experienced AEs per 100 patient-years. Most AEs (ALXN1840, 94.1%; SoC, 92.7%) were not serious. The most frequent AE with ALXN1840 was alanine aminotransferase increase (14.6%). Two deaths, considered unrelated to ALXN1840, were reported. ![Abstract O01 Figure 1][2]</img> Abstract O01 Figure 1 Conclusion ALXN1840 treatment for 48W provided superior Cu control to SoC and was generally well tolerated. Future data analysis of the 60-month open-label extension of this study will evaluate long-term efficacy and safety of ALXN1840. [1]: #F1 [2]: pending:yes" @default.
• W4296475494 created "2022-09-21" @default.
• W4296475494 creator A5002371143 @default.
• W4296475494 creator A5002664988 @default.
• W4296475494 creator A5005923405 @default.
• W4296475494 creator A5010258740 @default.
• W4296475494 creator A5013910778 @default.
• W4296475494 creator A5016423162 @default.
• W4296475494 creator A5017872044 @default.
• W4296475494 creator A5027268325 @default.
• W4296475494 creator A5036981869 @default.
• W4296475494 creator A5055670259 @default.
• W4296475494 creator A5058467867 @default.
• W4296475494 creator A5063226559 @default.
• W4296475494 creator A5063800558 @default.
• W4296475494 creator A5069717460 @default.
• W4296475494 creator A5073197069 @default.
• W4296475494 creator A5073289723 @default.
• W4296475494 creator A5086486292 @default.
• W4296475494 date "2022-09-01" @default.
• W4296475494 modified "2023-09-26" @default.
• W4296475494 title "O01 Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial" @default.
• W4296475494 doi "https://doi.org/10.1136/gutjnl-2022-basl.1" @default.
• W4296475494 hasPublicationYear "2022" @default.
• W4296475494 type Work @default.
• W4296475494 citedByCount "0" @default.
• W4296475494 crossrefType "proceedings-article" @default.
• W4296475494 hasAuthorship W4296475494A5002371143 @default.
• W4296475494 hasAuthorship W4296475494A5002664988 @default.
• W4296475494 hasAuthorship W4296475494A5005923405 @default.
• W4296475494 hasAuthorship W4296475494A5010258740 @default.
• W4296475494 hasAuthorship W4296475494A5013910778 @default.
• W4296475494 hasAuthorship W4296475494A5016423162 @default.
• W4296475494 hasAuthorship W4296475494A5017872044 @default.
• W4296475494 hasAuthorship W4296475494A5027268325 @default.
• W4296475494 hasAuthorship W4296475494A5036981869 @default.
• W4296475494 hasAuthorship W4296475494A5055670259 @default.
• W4296475494 hasAuthorship W4296475494A5058467867 @default.
• W4296475494 hasAuthorship W4296475494A5063226559 @default.
• W4296475494 hasAuthorship W4296475494A5063800558 @default.
• W4296475494 hasAuthorship W4296475494A5069717460 @default.
• W4296475494 hasAuthorship W4296475494A5073197069 @default.
• W4296475494 hasAuthorship W4296475494A5073289723 @default.
• W4296475494 hasAuthorship W4296475494A5086486292 @default.
• W4296475494 hasConcept C126322002 @default.
• W4296475494 hasConcept C168563851 @default.
• W4296475494 hasConcept C197934379 @default.
• W4296475494 hasConcept C203092338 @default.
• W4296475494 hasConcept C2776231509 @default.
• W4296475494 hasConcept C2779134260 @default.
• W4296475494 hasConcept C535046627 @default.
• W4296475494 hasConcept C71924100 @default.
• W4296475494 hasConcept C90924648 @default.
• W4296475494 hasConceptScore W4296475494C126322002 @default.
• W4296475494 hasConceptScore W4296475494C168563851 @default.
• W4296475494 hasConceptScore W4296475494C197934379 @default.
• W4296475494 hasConceptScore W4296475494C203092338 @default.
• W4296475494 hasConceptScore W4296475494C2776231509 @default.
• W4296475494 hasConceptScore W4296475494C2779134260 @default.
• W4296475494 hasConceptScore W4296475494C535046627 @default.
• W4296475494 hasConceptScore W4296475494C71924100 @default.
• W4296475494 hasConceptScore W4296475494C90924648 @default.
• W4296475494 hasLocation W42964754941 @default.
• W4296475494 hasOpenAccess W4296475494 @default.
• W4296475494 hasPrimaryLocation W42964754941 @default.
• W4296475494 hasRelatedWork W1974741395 @default.
• W4296475494 hasRelatedWork W2507295142 @default.
• W4296475494 hasRelatedWork W2959603226 @default.
• W4296475494 hasRelatedWork W2980596691 @default.
• W4296475494 hasRelatedWork W3159250744 @default.
• W4296475494 hasRelatedWork W3195440323 @default.
• W4296475494 hasRelatedWork W4256514411 @default.
• W4296475494 hasRelatedWork W4283740305 @default.
• W4296475494 hasRelatedWork W4292236216 @default.
• W4296475494 hasRelatedWork W2083697902 @default.
• W4296475494 isParatext "false" @default.
• W4296475494 isRetracted "false" @default.
• W4296475494 workType "article" @default.